About Ubiquitin carboxyl-terminal hydrolase isozyme L3
Ubiquitin carboxyl-terminal hydrolase isozyme L3 (UCHL3) is a protein
from Homo sapiens identified by UniProt accession
P15374, 230 residues long.
MolForge cross-references it against 0 known binders and
139 disease associations.
Target properties
| Protein name | Ubiquitin carboxyl-terminal hydrolase isozyme L3 |
|---|
| UniProt accession | P15374 |
|---|
| Gene | UCHL3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 230 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (139)
Diseases linked to this target (Open Targets).
- respiratory tract infectious disorder · score 0.24
- sinusitis · score 0.19
- breast adenocarcinoma · score 0.18
- mean corpuscular volume · score 0.16
- appendicular lean mass · score 0.15
- mean corpuscular hemoglobin · score 0.13
- clear cell renal carcinoma · score 0.10
- non-small cell lung carcinoma · score 0.10
- hepatocellular carcinoma · score 0.10
- erythrocyte count · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P15374-F1 | alphafold | PREDICTED | 94.75 | — |
Amino-acid sequence (230 residues)
MEGQRWLPLE ANPEVTNQFL KQLGLHPNWQ FVDVYGMDPE LLSMVPRPVC AVLLLFPITE KYEVFRTEEE EKIKSQGQDV TSSVYFMKQT ISNACGTIGL IHAIANNKDK MHFESGSTLK KFLEESVSMS PEERARYLEN YDAIRVTHET SAHEGQTEAP SIDEKVDLHF IALVHVDGHL YELDGRKPFP INHGETSDET LLEDAIEVCK KFMERDPDEL RFNAIALSAA
Explore Ubiquitin carboxyl-terminal hydrolase isozyme L3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets